These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36776661)

  • 21. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics.
    Limdi JK; Farraye FA
    Crohns Colitis 360; 2021 Jul; 3(3):otab015. PubMed ID: 36776664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
    Bansback N; Curtis JR; Huang J; He Z; Evans M; Johansson T; Michaud K; Schmajuk G; Liao KP
    ACR Open Rheumatol; 2020 Feb; 2(2):79-83. PubMed ID: 32043831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease.
    Sánchez-Hernández JG; Rebollo N; Martin-Suarez A; Calvo MV; Muñoz F
    Br J Clin Pharmacol; 2020 Jun; 86(6):1165-1175. PubMed ID: 32022291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data.
    Birck MG; Lukusa L; Choquette D; Boire G; Maksymowych WP; Singh H; Afif W; Bernatsky S
    BMC Rheumatol; 2024 Sep; 8(1):47. PubMed ID: 39343928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
    Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
    Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022.
    Roberts ET; Li J; Bansback N; Tseng CW; Shiboski S; Schmajuk G; Yazdany J
    Arthritis Rheumatol; 2024 Dec; 76(12):1739-1742. PubMed ID: 39077797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis.
    Hanrahan C; Lee T
    Am J Health Syst Pharm; 2021 Mar; 78(8):697-704. PubMed ID: 33599738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.